282 related articles for article (PubMed ID: 33972242)
1. Pharmacokinetics and Antifungal Activity of Echinocandins in Ascites Fluid of Critically Ill Patients.
Welte R; Oberacher H; Gasperetti T; Pfisterer H; Griesmacher A; Santner T; Lass-Flörl C; Hörtnagl C; Leitner-Rupprich S; Aigner M; Lorenz I; Schmid S; Edlinger M; Eller P; Dankl D; Joannidis M; Bellmann R
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0256520. PubMed ID: 33972242
[TBL] [Abstract][Full Text] [Related]
2. Penetration of echinocandins into wound secretion of critically ill patients.
Gasperetti T; Welte R; Oberacher H; Marx J; Lorenz I; Schellongowski P; Staudinger T; Burgmann K; Eller P; Santner T; Griesmacher A; Pfisterer H; Eschertzhuber S; Aigner M; Joannidis M; Bellmann R
Infection; 2021 Aug; 49(4):747-755. PubMed ID: 33877638
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
Gioia F; Gomez-Lopez A; Alvarez ME; Gomez-García de la Pedrosa E; Martín-Davila P; Cuenca-Estrella M; Moreno S; Fortun J
Int J Infect Dis; 2020 Dec; 101():24-28. PubMed ID: 32937195
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
7. Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.
Welte R; Eller P; Lorenz I; Joannidis M; Bellmann R
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29439960
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
9. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
10. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
12. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
13. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
14. Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex.
Marx J; Welte R; Gasperetti T; Moser P; Beer R; Ortler M; Jeske M; Stern R; Pomaroli A; Joannidis M; Bellmann R
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340985
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.
Walraven CJ; Bernardo SM; Wiederhold NP; Lee SA
Med Mycol; 2014 Feb; 52(2):131-139. PubMed ID: 24576999
[TBL] [Abstract][Full Text] [Related]
16. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
17. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
[TBL] [Abstract][Full Text] [Related]
19. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
